Business
Delcath Systems Reports First Quarter 2025 Results and Business Highlights
QUEENSBURY, N.Y., May 08, 2025--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025.
About this update from Delcath Systems, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/f663968ffc57be7c850890228c3e4273"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QuKwc6EzakHjWM2aXbwyKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f663968ffc57be7c850890228c3e4273","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7mt8W3J0li7J2RcWVocMCw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/f663968ffc57be7c850890228c3e4273","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Conference Call Today at 8:30 a.m. Eastern Time","length":47,"tagName":"p","attribs":{}},{"type":"text","content":"QUEENSBURY, N.Y., May 08, 2025--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025.","length":338,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Financial Results","length":36,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024","length":87,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024","length":92,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024","length":88,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":180,"olType":false}]},{"val":[{"type":"text","content":"Gross margins of 86%, compared to 71% in the first quarter of 2024","length":66,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net income of $1.1 million, compared to a net loss of $11.1 million in the same quarter of 2024","length":95,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Non-GAAP positive adjusted EBITDA in the first quarter of $7.6 million, compared to a l...